Blog Posts
June 23, 2023

The Art of Competitive Intelligence: Pharma's Secret Playbook to Staying Ahead of the Game

Blog Posts
June 23, 2023

The Art of Competitive Intelligence: Pharma's Secret Playbook to Staying Ahead of the Game

Author
Neneh Vannitamby, MD
Medical Writer

In the fast-paced and complex world of the pharmaceutical industry, being ahead of the curve is not just a competitive advantage - it's a necessity. This is where the art of competitive intelligence (CI) comes into play, a strategic chess match where pharma teams use knowledge and insights to outmaneuver their competitors.

Competitive intelligence involves the collection, analysis, and dissemination of information about competitors, markets, products, and more. In the pharmaceutical industry, this takes a more complex form.

Let's dive into the intricacies of how pharma teams wield this tool to stay ahead of the game.

1.    The Scope of CI in Pharma

In pharma, competitive intelligence not only focuses on direct competitors but also on the regulatory landscape, technological innovations, patent cliffs, clinical trials, and market trends.This comprehensive approach helps pharma companies to navigate complex environments, anticipate change, and take proactive measures.

2.    The Significance of Regulatory Intelligence

Regulatory intelligence is an integral aspect of CI in pharma. It involves understanding the shifting sands of regulatory policies, both domestically and internationally. This knowledge is critical in ensuring a smooth approval process for new drugs, navigating compliance issues, and developing strategies for market entry.

3.    The Role of Technological Intelligence

Staying abreast of technological advancements is another facet of competitive intelligence in the pharmaceutical industry.For instance, the rise of AI and precision medicine has significantly altered the landscape of drug discovery and development. Companies that effectively leverage these technological trends can gain a significant competitive advantage.

4.    The Power of Market Intelligence

Market intelligence allows pharma companies to understand their consumers, the demand for their products, and the key market trends. These insights enable them to tailor their products to meet consumer needs and to identify new market opportunities.

The art of competitive intelligence in pharma is a complex yet essential strategy that requires continuous monitoring, deep analysis, and strategic thinking. But when done right, it provides a roadmap to success - keeping pharma teams not just in the game, but ahead of it.

In the competitive arena of the pharmaceutical industry, knowledge is power, and competitive intelligence is the key to unlocking that power.

Whether it's understanding regulatory changes, staying ahead of technological advancements, navigating patent landscapes, or decoding market trends, the companies that master the art of competitive intelligence are those that will lead the industry into the future.

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.